Navigation Links
Signa Profile 0.2T

ProductsSigna Profile 0.2T
Company GE Healthcare
Item Signa Profile 0.2T
Features Wide open bore to easily accommodate claustrophobic or large patients. Very high homogeneity magnet. Strong & fast gradient system at 15 mt/m & SR30 for fast scans, thin slices, small FOV. Broad choice of advanced coils including quadrature & multi-channel phased-array. Most recent & advanced sequences like EPI diffusion, SSFSE, FIESTA, Fat water Separation. Signa Profile is designed to make things easier through its flexible sitting. User friendly and flexible operator interface. 64 bit dual CPU achieves image reconstruction time of 0.05 seconds.
Description Signa Profile is built on the Signa foundation to deliver speed & image quality.
Info GE HealthcareCall GE Healthcare to buy products (US and Canada only; other locations use number below) USACanada1-866-903-4021

Customer Service: 1-800-957-6837
Web site: http://www.gehealthcare.com/

Related medicine products :

1. BacT/Alert 3D Signature
2. 0.5T Signa Contour/I
3. HEMOCHRON Signature Elite Microcoagulation System
4. HEMOCHRON Jr. Signature+ Microcoagulation System
5. HEMOCHRON Jr. Signature Microcoagulation System
6. Signa Conductive Gel
7. Signature Edition GOLD Infusion System
8. Signature Flip-Up Loupes - Titanium Frame
9. Signature Flip-Up Loupes - SV Sport Frame
10. ThinProfile Design Eyelid Implants
11. Lorenz 2.0 mm Low Profile Titanium
...orporate a layered design unique in the industry. ...ent stray electrosurgical burns along the shaft of...pacitive coupling; a well-documented patient safet...nstruments provides a neutral return path for capa...
...orporate a layered design unique in the industry. ...ent stray electrosurgical burns along the shaft of...pacitive coupling; a well-documented patient safet...nstruments provides a neutral return path for capa...
...orporate a layered design unique in the industry. ...ent stray electrosurgical burns along the shaft of...pacitive coupling; a well-documented patient safet...nstruments provides a neutral return path for capa...
The Auto Suture™ ExtraHand™ balloon retractor is designed to be used during open surgery, gasless endoscopy, as well as endoscopy with gas insufflation.
Medicine Products:
(Date:9/5/2008)...G, Pa., Sept. 5 /PRNewswire-USNewswire/ -- Childre...r access to comprehensive,services to protect thei...n,in grants that were announced today by the Depar...vices for children and families, the department,be...ren,s Services Planning,initiative, ICSP, in 2004....
(Date:9/5/2008)..., Md., Sept. 5 /PRNewswire-USNewswire/ -- The Heal...day announced $39 million in grants to,increase an...centers., "These grants continue President Bush,s...whose services now reach more economically,vulnera...r before," HRSA,Administrator Elizabeth M. Duke sa...
(Date:9/5/2008)...ontrolled, but you need to know what triggers them...thDay News) -- If you are one of the 36 million Am...is nowhere in the United States that is free from ... shows. , Allergies don,t only happen in the sp...ell. In the fall, the most challenging cities to l...
(Date:9/5/2008)...N, Sept. 5 /PRNewswire-USNewswire/ -- Speaker Nanc...upport of the aims of the "Stand,Up to Cancer" tel...re is not a person in our country who has not seen...s 565,000 Americans annually, and each,year there ... must work,together to make eradicating the scourg...
Breaking Medicine News(10 mins):Health News:Pennsylvania Counties Receive Grants to Improve Services for Children 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:No Place Safe From Allergies 2
...Fund (IMF) said that there would be a significant ... set aside a plan of action against the avian flu....g. It said that a pandemic would trigger sharp fal...dities, tourism and trade would recede and lead to...
...ty at Buffalo have been able to identify two key c...the amount of oral bone loss in future. Oral bone ...d a tooth is vital to hold it in place. // Resear... than a 100 patients and related them with the lev...
...Sjogren's syndrome using saliva-based tests will s...ented at the yearly meeting of American Associatio...autoimmune disorder that is characterized by dry e... can catch someone with oral cancer at stage 2 ins...
...hat the Americans who are old today are much healt...disabilities later in life and will get healthier ...be like the next generation would have older peopl...ving access to a large range of situations and wid...
Other Medicine News:
(Date:9/4/2008)...t. 4 /- BioForm Medical,In...al clinical study of,Polidocanol, conducted in Ger...k KREUSSLER & Co. GmbH (Kreussler), successfully m...ed to FDA as part of a New Drug Application,(NDA) ...e EASI (Efficacy and safety of,Aethoxysklerol comp...
(Date:9/4/2008).... 4 /- Southern Research Institute,to...th (NIH) has selected,the organization to particip...Production Center Network (MLPCN). The MLPCN -- a ...olecular Libraries Program which is,designed to be...f the human,genome and validate future targets for...
(Date:9/4/2008)...es potent antiviral activity and favorable safety ...E, Mass., Sept. 4 /- Idenix...maceutical company engaged,in the discovery and de...l,and other infectious diseases, today announced t...aluating IDX899, a non-nucleoside reverse,transcri...
(Date:9/3/2008)...n Asked. Wrong Children Studied. Wrong,Conclusions...ire/ -- A Centers for Disease,Control and Preventi...ink,between the MMR vaccine and autism. The Nation...othing to dispel the growing public concern over a...tions concerning design,and methodology., For yea...
Breaking Medicine Technology:338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 2338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 3338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 4338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 5Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 2Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 3Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 4Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 2Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 3Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 4CDC Misses Target With Flawed MMR/Autism Study 2Arbios Receives Conditional Approval from the FDA to Initiate Pivotal Clinical Trial for SEPET 28TM 29 1411 1Arbios Receives Conditional Approval from the FDA to Initiate Pivotal Clinical Trial for SEPET 28TM 29 1411 2Arbios Receives Conditional Approval from the FDA to Initiate Pivotal Clinical Trial for SEPET 28TM 29 1411 3Arbios Receives Conditional Approval from the FDA to Initiate Pivotal Clinical Trial for SEPET 28TM 29 1411 4Otho S A Sprague Memorial Institute awards Rush 24230 000 for childhood obesity prevention 12503 1Otho S A Sprague Memorial Institute awards Rush 24230 000 for childhood obesity prevention 12503 2New Stroke Therapies Show Promise 12500 1New Stroke Therapies Show Promise 12500 2New Stroke Therapies Show Promise 12500 3EPA Funds Grants for Lead Poisoning Prevention Projects in Two Ohio Communities 12497 1
...m the Companies, Novel Heat Shock Protein 90 Inhib...ty, and Biological,Activity , CAMBRIDGE, Mass. and...-- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) an...dated interim,results from a Phase I clinical tria...inhibitor, IPI-504, in patients with relapsed,ref...
... show UVIDEM was well-tolerated with signs of dura...-, IRVINE, Calif., June 05, 2007 /PRNewswire-First...ary results from a Phase II,UVIDEM (IDD-3) melanom... showed that UVIDEM was well tolerated with eviden... patients with,progressive metastatic melanoma. , ...
Other Medicine Technology:Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 2Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 3Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 4Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 5Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 6Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 7IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 2IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 3IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 4IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 5